The Chinese cosmetics industry has seen numerous narratives centered around ingredients over the past few years. From traditional botanical extracts to synthetic biology, a range of "Chinese ingredients" have stepped into the spotlight, reshaping the global skincare market discourse through tangible technological breakthroughs. Within this ingredient race, the sensitive skin segment has become particularly saturated. However, stripping away the marketing rhetoric reveals that the approaches of most brands are highly convergent: barrier repair, soothing hydration, and irritation reduction. While these methods hold value, they remain largely superficial, akin to pouring water on a burning house without addressing the root cause of the fire. Is there a more fundamental, root-cause solution for sensitive skin? In response to this question, a low-profile innovator, MARTEMPO, provides a scientifically-proven answer that targets the core issue. Its confidence stems from a patented ingredient, Mytilus Calcium Peptide CAPCS®, refined over a decade and derived from deep-sea mussels. Utilizing the world's first topical calcium ion repair technology, it breaks the industry's cycle of homogeneous "pseudo-repair" solutions.
As the era of traffic红利 peaks and "ingredient-savvy" consumers evolve into demanding "evidence-savvy" ones, MARTEMPO is poised not only to redefine the industry standards for sensitive skin repair but also to set a new benchmark for ingredient innovation in China.
**The Sensitive Skin "Dark Horse" Ingredient: Solving the Global Challenge of Calcium Ion Transdermal Delivery**
In the marketing lexicon of the cosmetics industry, "sensitive skin" is an overused concept. To cater to the anxieties of ingredient-focused consumers, brands have been frantically incorporating ceramides, squalane, and hyaluronic acid, as if merely thickening the skin's "wall" would lead to self-repair. Yet, any dermatologist would reveal a truth obscured by marketing: the essence of sensitive skin is not a broken wall, but a fire burning *inside* the wall. This fire is "inflammation." Whether it's atopic dermatitis (AD) or frustrating chronic cheilitis, the root cause lies in the immune system's overreaction. When inflammatory factors (like IL-4, IL-31) are released rampantly in the deeper layers of the skin, simply applying oils to the epidermis is like painting over a burning house—it may look good superficially but hides a serious underlying hazard. A typical example is cheilitis—daily dryness, flaking, stinging after applying lipstick, and recurring scaling around the lip border. Most people attribute this to "internal heat" or "dehydration," but clinically, these are early signs of chronic cheilitis. Without intervention, the inflammation can persist and become stubborn cheilitis, which is very difficult to manage.
MARTEMPO's breakthrough lies in its choice to "put out the fire" rather than follow the industry's habit of "painting over it." It starts from the fundamental dermatological logic: without anti-inflammatory action, there is no true repair. By targeting root-cause anti-inflammation, it directly rewrites the logic of sensitive skin repair. The medical value of calcium ions for anti-inflammatory, anti-allergic, and rapid itch-relief effects has long been proven, but was previously limited to injectable use, not topical application. Mytilus Calcium Peptide CAPCS® employs the world's first topical calcium ion repair technology, enabling efficient transdermal absorption of calcium ions for the first time, effectively packaging medical-grade anti-inflammatory power into skincare products. This technology is unprecedented in the global cosmetics industry.
Furthermore, unlike common mussel adhesive protein-based ingredients on the market, Mytilus Calcium Peptide CAPCS® is not a single-structure protein but a complex system with defined ionic activity and signaling regulation functions. Its mechanism of action has been published in the international SCI journal *International Journal of Molecular Sciences*. Research indicates that CAPCS® achieves a groundbreaking combination of natural active calcium ions, high-activity penetration enhancement, and antimicrobial peptides. It can inhibit inflammation and immune responses by modulating Th cells and TLR2/TLR4 signaling pathways, intervening at the source of sensitivity symptoms.
The significance of this underlying technology extends far beyond the birth of a "new ingredient." It signifies the cosmetics industry's first possession of a topical, transdermal, and verifiable calcium ion delivery system. In the sensitive skin anti-inflammatory arena, Mytilus Calcium Peptide CAPCS® is not merely an "upgraded version" but a "disruptive version," elevating sensitive skin repair from "superficial soothing" to a new height of "root-cause healing."
**Raising the Industry Bar: Aligning with Pharmaceutical-Grade Efficacy Standards**
If ingredient innovation reflects R&D capability, the choice of clinical validation system directly reveals a brand's standards for itself. In the cosmetics industry, most brands are content with in-vitro tests or consumer self-assessment questionnaires. MARTEMPO, however, has chosen a different path of "medical evidence-based" validation, actively aligning with pharmaceutical clinical pathways and adopting verification methods from the medical field. What does this mean? It means MARTEMPO not only proves the efficacy of the CAPCS® ingredient but also dares to compare it directly with pharmaceuticals under strictly controlled conditions. This "upward-compatible" clinical strategy essentially elevates the efficacy verification standards of the cosmetics industry to the level of pharmaceutical products.
For instance, in a study conducted at Beijing Friendship Hospital, Mytilus Calcium Peptide CAPCS® was shown to have effects similar to the weak corticosteroid hydrocortisone in treating atopic dermatitis (AD), with superior itch-relief properties. In validation studies at West China Hospital, Sichuan University, it demonstrated significant efficacy against AD by modulating Th cells and TLR2/TLR4 pathways to inhibit inflammation and immune responses, with effects approaching those of the medium-potency corticosteroid desonide. More importantly, for pediatric AD patients, CAPCS® could even help reduce the usage of desonide.
In the specific niche of lip care efficacy, MARTEMPO pushes clinical standards even higher. Addressing the industry's lack of lipsticks with proven efficacy for cheilitis, the brand launched the Mytilus Essence CAPCS® Calcium Peptide Repair Lip Balm and initiated a single-center randomized double-blind controlled clinical trial—the highest level in the cosmetic efficacy evaluation pyramid. Its comparator was tacrolimus, a first-line drug for treating moderate to severe cheilitis. Results showed the product significantly improved lip inflammation symptoms with better safety. This is not just a victory in data but a reshaping of industry standards. MARTEMPO demonstrates with its efficacy that "effective and safe" is no longer just marketing talk but verifiable, reproducible, and traceable real capability. This will set a new benchmark for the entire sensitive skin segment.
**The Authoritative Coronation of a "Chinese Ingredient"**
The true value of an ingredient is ultimately measured by the weight of the recognition it receives. The accolades accumulated by Mytilus Calcium Peptide CAPCS® are considered "scarce assets" in the domestic sensitive skin market. First is continuous validation from academia. To date, four clinical efficacy papers on CAPCS® have been published, two of which appeared in the *Chinese Journal of Dermatology*, the most authoritative dermatology journal in China, while research on its soothing mechanism was published in the international SCI journal *International Journal of Molecular Sciences*. For a cosmetic ingredient, such density and quality of academic publications place it firmly at the industry's forefront.
More critical is recognition from clinical application. Due to its significant efficacy and safety in treating atopic dermatitis, Mytilus Calcium Peptide CAPCS® was included in the *Expert Consensus on Rational Use of Topical Agents for Atopic Dermatitis and Patient Guidance*. This is not corporate promotion but an officially released guidance document reviewed by industry experts. Inclusion in an expert consensus signifies a transition from "company-proven" to "industry-recognized." On a broader public awareness level, CAPCS® also received joint certification from Xinhua News Agency and Shangpu, becoming a nationally authorized representative of "Chinese ingredients."
It is evident that from clinical validation by top-tier medical institutions to endorsements from state-level media, Mytilus Calcium Peptide CAPCS® has built a comprehensive trust system spanning research, clinical practice, and public communication. All this recognition culminates in MARTEMPO's standing within the industry. On April 24th, MARTEMPO was invited for the eighth consecutive year to the Annual Conference of the Chinese Society of Dermatology—a premier gathering in the domestic dermatology field, attended by over 90% of China's authoritative dermatologists—which in itself is the most direct affirmation of CAPCS®'s scientific value.
Notably, based on the technological foundation of this ingredient, MARTEMPO has also extended its application to public welfare, using technology to address needs beyond commerce. The brand's "Spring Light Project," in collaboration with the Shanghai Debo Butterfly Children Care Center, focuses on individuals with Epidermolysis Bullosa, a rare skin disorder. The anti-inflammatory and gentle repair properties of its core ingredient, CAPCS®, offer new possibilities for at-home efficacy skincare for these "butterfly children."
In an increasingly crowded and浮躁 sensitive skin market, those who endure are never the best marketers. The dark horse ingredient from the deep sea, Mytilus Calcium Peptide CAPCS®, is proving with substance that good ingredients need no hype, and good products speak for themselves. The future of Chinese ingredients belongs to such grounded, robust, and compassionate original forces.